239 related articles for article (PubMed ID: 31974142)
1.
Morieri ML; Shah HS; Sjaarda J; Lenzini PA; Campbell H; Motsinger-Reif AA; Gao H; Lovato L; Prudente S; Pandolfi A; Pezzolesi MG; Sigal RJ; Paré G; Marcovina SM; Rotroff DM; Patorno E; Mercuri L; Trischitta V; Chew EY; Kraft P; Buse JB; Wagner MJ; Cresci S; Gerstein HC; Ginsberg HN; Mychaleckyj JC; Doria A
Diabetes; 2020 Apr; 69(4):771-783. PubMed ID: 31974142
[TBL] [Abstract][Full Text] [Related]
2. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
3. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
4. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
5. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Zhu L; Hayen A; Bell KJL
Cardiovasc Diabetol; 2020 Mar; 19(1):28. PubMed ID: 32138746
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
7. Do persons with diabetes benefit from combination statin and fibrate therapy?
Rosenblit PD
Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
[TBL] [Abstract][Full Text] [Related]
8. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
Diabetes Care; 2016 Jul; 39(7):1089-100. PubMed ID: 27289122
[TBL] [Abstract][Full Text] [Related]
9. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
11. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Foucher C; Rattier S; Flavell DM; Talmud PJ; Humphries SE; Kastelein JJ; Ayyobi A; Pimstone S; Frohlich J; Ansquer JC; Steiner G;
Pharmacogenetics; 2004 Dec; 14(12):823-9. PubMed ID: 15608561
[TBL] [Abstract][Full Text] [Related]
12. The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Krysiak R; Gdula-Dymek A; Marek B; Okopień B
Endokrynol Pol; 2016; 67(2):190-6. PubMed ID: 26884290
[TBL] [Abstract][Full Text] [Related]
13. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Krysiak R; Gdula-Dymek A; Marek B; Okopień B
Endokrynol Pol; 2015; 66(3):224-30. PubMed ID: 26136131
[TBL] [Abstract][Full Text] [Related]
15. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
16. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
17. [What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].
Rosolová H
Vnitr Lek; 2015 Nov; 61(11):971-5. PubMed ID: 26652786
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Linz PE; Lovato LC; Byington RP; O'Connor PJ; Leiter LA; Weiss D; Force RW; Crouse JR; Ismail-Beigi F; Simmons DL; Papademetriou V; Ginsberg HN; Elam MB
Diabetes Care; 2014; 37(3):686-93. PubMed ID: 24296848
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Margolis KL; O'Connor PJ; Morgan TM; Buse JB; Cohen RM; Cushman WC; Cutler JA; Evans GW; Gerstein HC; Grimm RH; Lipkin EW; Narayan KM; Riddle MC; Sood A; Goff DC
Diabetes Care; 2014 Jun; 37(6):1721-8. PubMed ID: 24595629
[TBL] [Abstract][Full Text] [Related]
20. Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.
Koopal C; Visseren FLJ; Westerink J; van der Graaf Y; Ginsberg HN; Keech AC
Diabetes Care; 2018 Jun; 41(6):1244-1250. PubMed ID: 29472432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
